enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Hydralazine/isosorbide dinitrate - Wikipedia

   en.wikipedia.org/wiki/Hydralazine/isosorbide_di...

   A new paper was published on these findings and MedCo filed for a new patent for the drug as a treatment for heart failure specifically in black patients. [ 4 ] [ 7 ] [ 8 ] The new patent and the old patent were then licensed to a company called NitroMed, which ran a clinical called the African-American Heart Failure Trial (A-HeFT), the results ...

3. Windtree Therapeutics Heart Failure Drug Candidate Improves ...

   www.aol.com/windtree-therapeutics-heart-failure...

   On Wednesday, Windtree Therapeutics, Inc. (NASDAQ:WINT) released topline results from its Phase 2b SEISMiC Extension Study of istaroxime for patients in early cardiogenic shock due to heart failure.

4. Sacubitril/valsartan - Wikipedia

   en.wikipedia.org/wiki/Sacubitril/valsartan

   Sacubitril/valsartan, sold under the brand name Entresto among others, is a fixed-dose combination medication for use in heart failure.It consists of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker valsartan.

5. Omecamtiv mecarbil - Wikipedia

   en.wikipedia.org/wiki/Omecamtiv_mecarbil

   Omecamtiv mecarbil effectively relieves symptoms and enhances the quality of life of systolic heart failure patients. It improved cardiac performance in short-term studies; [ 2 ] [ 3 ] however, while the drug reduced the risk of hospitalization or other urgent care for heart failure by 8% in high-risk patients in the Phase III clinical trial ...

6. Cytokinetics heart failure drug succeeds but slightly higher ...

   www.aol.com/news/cytokinetics-heart-failure-drug...

   Details presented at annual meeting of the American Heart Association (AHA) held virtually this year follow the release in October of initial results for the 8,256-patient trial. The benefit ...

7. Cytokinetics heart drug succeeds in closely watched study ...

   www.aol.com/news/cytokinetics-heart-disease-drug...

   (Reuters) -Cytokinetics said on Wednesday that its experimental heart disease drug met the main goal of a keenly awaited late-stage study, putting it on track to compete with a rival treatment ...